Ozempic
- Active ingredient
- semaglutide
- Class
- GLP-1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Maker
- Novo Nordisk
Educational only. This is educational, not medical advice. Everyone's body responds differently. Talk to your clinician before starting, stopping, changing, or tapering any medication, and work with your physician and a registered dietitian to personalize your approach.
Overview
Ozempic is the diabetes brand of semaglutide, a GLP-1 receptor agonist. It mimics the gut hormone GLP-1, which is released after eating and signals fullness to the brain, slows how fast the stomach empties, and helps regulate blood sugar.
Because that combination of effects also reduces appetite and the intrusive thoughts about food many people call 'food noise', semaglutide produces meaningful weight loss, which is why Ozempic is widely prescribed off-label for weight and why the same molecule is sold as Wegovy for weight management.
Approval and use
| Approved for | Type 2 diabetes (and cardiovascular risk reduction in adults with type 2 diabetes and heart disease) |
| Weight use | Weight loss with Ozempic specifically is off-label; the same molecule is approved for weight management under the brand Wegovy. |
Typical titration (informational)
The label starts low and steps up over months to limit nausea, beginning at 0.25 mg weekly for four weeks.
Doses then increase in stages (commonly 0.5 mg, 1 mg, up to 2 mg) at intervals, with the maintenance dose chosen by the prescriber.
This schedule is set by your clinician based on your response and tolerance; it is shown here only as background, not as instructions.
Expected timeline
Appetite changes often appear within the first weeks, with weight loss accumulating over 6 to 12 months and tending to plateau. In trials of semaglutide for weight management, average loss was in the mid-teens percentage of body weight.
Common side effects
- Nausea (most common, usually early and improving with time)
- Constipation or diarrhea
- Vomiting and reflux
- Fatigue early in titration
- Rare but serious risks (pancreatitis, gallbladder issues) that your clinician monitors for
What happens when you stop Ozempic
When semaglutide is stopped, the appetite-suppressing signal goes away. Ghrelin (the hunger hormone) rebounds, food noise tends to return, and the body's lowered metabolic rate from weight loss persists, so hunger rises just as the calorie need stays low.
Across studies, people regained roughly 60 to 75 percent of their lost weight within about a year of stopping, with the steepest regain in the first 3 to 6 months. This is physiology, not failure, and it is the exact window GLP-Done is built around.
Cost
List price without insurance has historically run several hundred to over a thousand dollars a month; coverage, manufacturer savings programs, and pharmacy varies widely. Verify current pricing directly.
Frequently asked questions
Is Ozempic the same as Wegovy?
Both are semaglutide. Ozempic is the diabetes brand; Wegovy is the higher-dose brand approved for weight management. The active molecule is the same.
Will I regain weight if I stop Ozempic?
Most people regain a substantial share of lost weight within about a year of stopping, because appetite hormones rebound and metabolic rate stays lowered. Evidence-based habits (protein, strength, sleep, consistency) and clinician-guided options like tapering can soften the rebound. This is educational, not medical advice.
Sources & further reading
Every claim on this page is drawn from peer-reviewed research, clinical trials, or recognized health authorities. Read the source before making any decision about your health.
- [1]Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regressionNIH/PMC
- [2]Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysisNIH/PMC
- [3]Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight LossNIH/PMC